13.36 USD
↘ 0.40 (2.91%)AT CLOSE (11:59 AM EDT)
Janux Therapeutics, Inc. Common Stock
JANXNASDAQ • USD
13.37
↗ 0.01 (0.04%)
POST MARKET (AS OF 07:42 PM EDT)
Post Market
AS OF 07:42 PM EDT
13.37
↗ 0.01 (0.04%)
Market: CLOSED
Open?$13.76
High?$13.83
Low?$13.16
Prev. Close?$13.76
Volume?490.6K
Avg. Volume?914.7K
VWAP?$13.43
Rel. Volume?0.54x
Bid / Ask
Bid?$11.48 × 100
Ask?$15.19 × 100
Spread?$3.71
Midpoint?$13.34
Valuation & Ratios
Market Cap?814.8M
Shares Out?61.0M
Float?37.1M
Float %?61.6%
P/E Ratio?N/A
P/B Ratio?0.87
EPS?-$1.88
Dividend?0.00%
Ex-Dividend?N/A
Shares of Janux Therapeutics, Inc. Common Stock (JANX) are trading at $13.36. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. JANX is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Employees
108
Market Cap
814.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-06-11
Address
10955 VISTA SORRENTO PARKWAY
SAN DIEGO, CA 92130
Phone: (858) 751-4493
SAN DIEGO, CA 92130
Phone: (858) 751-4493
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?99
Momentum?50
Short Sent.?45
Piotroski F-Score?0/9Weak
Altman Z-Score?5.74Safe
Confidence?45%Low
Short InterestSqueeze Risk
Short % of Float?21.12%Squeeze Risk
Short Interest?7.8M
Days to Cover?9.7
Free Float37.1M
Avg Daily Volume810.5K
Settlement Date2026-05-15
Financial Health
Current Ratio?17.01Strong
Quick Ratio?17.01Strong
Cash Ratio?0.88Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?0.87CHEAP▾
Peers100
S&P97
P/S?59.33HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.9CHEAP▾
S&P97
EV/Sales?55.55HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-12.2%WEAK▾
S&P9
ROA?-11.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-78493000
Enterprise Value?$762.9M
Fundamentals ratios updated end of day